Cargando…
Risk factors for pneumonitis in patients treated with anti‐programmed death‐1 therapy: A case‐control study
Immune checkpoint blockade‐related pneumonitis is a rare but potentially life‐threatening adverse effect, but its risk factors are not completely understood. This case‐control study was conducted to identify pneumonitis risk factors in patients treated with anti‐PD1 monoclonal antibodies (mAbs), inc...
Autores principales: | Cui, Pengfei, Liu, Zhefeng, Wang, Guoqiang, Ma, Junxun, Qian, Yuanyu, Zhang, Fan, Han, Chun, Long, Yaping, Li, Ye, Zheng, Xuan, Sun, Danyang, Zhang, Jing, Cai, Shangli, Jiao, Shunchang, Hu, Yi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6089164/ https://www.ncbi.nlm.nih.gov/pubmed/29797416 http://dx.doi.org/10.1002/cam4.1579 |
Ejemplares similares
-
Genetic variants of SP‐D confer susceptibility to radiation pneumonitis in lung cancer patients undergoing thoracic radiation therapy
por: Xu, Li, et al.
Publicado: (2019) -
Genetic variants in the plasminogen activator inhibitor‐1 gene are associated with an increased risk of radiation pneumonitis in lung cancer patients
por: Liu, Bo, et al.
Publicado: (2017) -
Risk of immune‐related pneumonitis for PD1/PD‐L1 inhibitors: Systematic review and network meta‐analysis
por: Huang, Yafang, et al.
Publicado: (2019) -
Anti-PD-1 Therapy plus Chemotherapy and/or Bevacizumab as Second Line or later Treatment for Patients with Advanced Non-Small Cell Lung Cancer
por: Zhang, Fan, et al.
Publicado: (2020) -
Proteomics reveals the function reverse of MPSSS‐treated prostate cancer‐associated fibroblasts to suppress PC‐3 cell viability via the FoxO pathway
por: Zhang, Tingting, et al.
Publicado: (2021)